Allogeneic blood-derived NK cell therapy (NKGen Biotech)

N/A

Report date: 2024/06/20 17:08:13

Base Information

Drug NameAllogeneic blood-derived NK cell therapy (NKGen Biotech)
Drug Alias NameAnti-HER2 CAR NK-cell therapy (Nkmax/NKGen Biotech)Allogeneic CAR NK-cell therapy (Nkmax/NKGen Biotech)Chimeric antigen receptor-super natural killer cell therapies (NKGen Biotech)SNK-02SNK02 +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNKGen Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesNKGen Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A